Skip to main content

Valrubicin Pregnancy and Breastfeeding Warnings

Medically reviewed by Last updated on Apr 22, 2021.

Valrubicin is also known as: Valstar

Valrubicin Pregnancy Warnings

This drug should be used during pregnancy only if the benefit outweighs the risk.

US FDA pregnancy category: C

-All patients (male and female) of reproductive age should be advised to use an effective contraception method during the treatment period.
-If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.

Animal studies have revealed evidence of embryotoxicity and teratogenicity. There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Valrubicin Breastfeeding Warnings

Breastfeeding is not recommended during use of this drug.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The drug is highly lipophilic and any exposure of infants could pose serious health risks.

See references

References for pregnancy information

  1. "Product Information. Valstar (valrubicin)." Medeva Pharmaceuticals (2001):

References for breastfeeding information

  1. "Product Information. Valstar (valrubicin)." Medeva Pharmaceuticals (2001):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.